Burlingame, California —January 3, 2018— Collaborative Drug Discovery, provider of CDD Vault® web-based drug discovery informatics platform, announced they have been awarded a $1.5M Phase 2B SBIR grant titled “Comprehensive but simple encoding of bioassays to accelerate translational drug discovery”. These innovations are productized in the commercially available collaborative CDD Vault ELN (Electronic Laboratory Notebook) and a new, intelligent CDD Vault Assay Registration System (BioAssay Express technology is currently in partnership with early adopters).
The Patented BioAssay Express (BAE) technology (U.S. Patent No. 9,594,743 issued March 14, 2017) was used to convert 3500 MLPCN PubChem Assay protocols into an expert-annotated, machine readable database.
BioAssay Express has been well received by thought leaders wrestling with similar web-based, big data integration challenges at PubChem, ChEMBL, BioAssay Research Database (BARD), University of Miami, Stanford, UCSF, NCI, and National Center for Advancing Translational Sciences (NCATS), as well as with a number of major biopharmaceutical companies. “CDD is applying the same best practices in design, development, and secure collaboration which are the strong foundation of the entire CDD Vault platform to these new technologies. To date this approach has led to the four existing commercial modules CDD Vault Activity and Registration, Visualization, Inventory and ELN. With this new initiative, we’re building a highly differentiated, modern CDD Vault Assay Registration System,” said Barry A. Bunin, PhD, CDD CEO and the Principal Investigator (PI) on this latest grant.
Specific Aims for Phase 2B:
- Advance the BioAssay Express platform so that BAE version 2.0 can capture comprehensive assay protocol descriptions, including all the materials, sequential procedural steps and other details needed to thoroughly describe and reproduce experiments.
- Create and validate a suite of assay templates representing the major types of assay protocols, to systematize best practices embodied in the NIH Assay Guidance Manual and provide standardized scaffolds that simplify the task of annotating different types of assays.
- Develop a few initial applications, requested by prospective early customers, that exploit BAE 2.0 technology such as (a) identify ‘frequent hitters’, (b) visualize the relationships and differences among a pharma company’s portfolio of assays, (c) translate annotations into well-structured and complete text documents, and (d) prepare protocols for automated robotic execution.
CDD previously provided a strong proof-of-concept that one could use new automation technologies for comparison of assay conditions with the accuracy of existing manual mark-up methods (see: Open Access Publication, Interview, Blog, and the BAE Technology Introduction).
About this grant
The Phase 2B Small Business Innovation Research (SBIR) grant is part of a program to enable sharing of biological data. Award Number 2R44TR000185-04 from National Center for Advancing Translational Sciences as described on NIH Reporter supports this project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.
About Collaborative Drug Discovery, Inc.
CDD’s (www.collaborativedrug.com) flagship product, CDD Vault® is a modern web application for your chemical registration, assay data management and SAR analysis. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. CDD Vault® is continuously growing its technology most recently to include ELN, Model and API functionality.
A complete list of the 58 CDD publications/patents can be found online on our resources page: https://www.collaborativedrug.com/pages/resources.
For more information contact: Collaborative Drug Discovery, (650) 204-3084, [email protected].